Unlike other solid malignancies, tumor mutation burden and PD-L1 status in ccRCC are not predictive indicators of immune checkpoint therapy outcome (46), suggesting that dysfunctional immune responses associated with infiltrating immune cell types and states may be better predictors of clinical response and therapeutic resistance to immune checkpoint therapy in ccRCC. Here, CD274 is linked to nonpapillary renal cell carcinoma.